AI plaque analysis is changing cardiac care. In one case, a patient with “normal” labs had extensive non‑calcified plaque—data that shifted management toward aggressive LDL lowering. In-house #cvi42 processing returns results in seconds.
hubs.la/Q04k_HJx0
After EVAR we track sac diameter. But diameter sees the sac in one plane — it can grow in volume while width holds steady. New JVS data: early volume change predicts long-term diameter.
#EVAR#VascularSurgeryhubs.la/Q04kzxD90
3 questions to ask any CCTA plaque vendor before IT signs off:
1) End-to-end PHI data-flow for one study?
2) New BAA scope, or extension of systems you already manage?
3) When it's down, what's the reading-floor workflow?
hubs.la/Q04jGTxL0#CCTA#cvi42
3 questions any send-away CCTA plaque service forces on your security team:
1) Where does PHI sit, and for how long?
2) Do their audit logs reconcile with yours?
3) Is your data used to train models?
hubs.la/Q04jGVZy0#CCTA#DataPrivacy
Your cardiology team picked the plaque tool. IT inherits the rest — the BAA, the egress route, a new outbound PHI transfer for every CCTA.
A platform that runs plaque inside your environment changes the math.
hubs.la/Q04jGJlM0#CCTA#DataPrivacy
The most dangerous plaque is the one a calcium score can't see.
Soft, lipid-rich plaque ruptures. Calcium-only scoring is blind to it.
CT plaque analysis sees what CAC misses — and changes who gets a statin.
hubs.la/Q04hzSn20#CCTA#cvi42
Three questions to ask any CCTA vendor:
1) Plaque analysis in the same workspace, or separate login?
2) Quantitative metrics on every read, or selected cases?
3) Can you defend a stenosis-only report if the patient returns with ACS?
#CCTA#cvi42hubs.la/Q04gTqjx0
That's a wrap on CardioSUC 2026.
Workshop full. Cases pushed hard. cvi42 in the loop.
Gracias Montevideo. Hasta la próxima.
#CardioSUC2026#cvi42hubs.la/Q04gxtXm0
Three things the major CCTA trials tell us:
1) Plaque burden predicts MACE — stenosis doesn't.
2) LAP, positive remodeling, PCAT are detectable on standard CCTA.
3) SCOT-HEART 2 is now testing it for primary prevention.
#CCTA#cvi42hubs.la/Q04gTvh-0
If your CMR read stops at function, you're leaving the modality's biggest answer on the table.
LGE. T1/T2/ECV mapping. Quantitative perfusion. Tissue characterization, standardized.
See it on your studies:
hubs.la/Q04fL7zp0#CardiacMRI#LGE#cvi42
A lot of acute coronary events happen in patients already cleared on stenosis grade.
The plaque hadn't grown — but it was vulnerable.
CCTA can show you this. Standard reporting can't.
#CCTA#cvi42hubs.la/Q04gTs_40